Korsana Biosciences, Inc. is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases. Its lead program, KRSA-028, is an investigational shuttled antibody targeting amyloid beta for the treatment of Alzheimer's disease. The company became publicly traded in September 2026 through a merger with Cyclerion Therapeutics, Inc.
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $945.53 | A | |
| $16.99 | A | |
| $13.33 | A |